Trends in Over-the-Counter Nicotine Replacement Therapy Sales, U.S., 2017‒2020

Published:January 20, 2023DOI:


      Few studies have examined trends in over-the-counter U.S. Food and Drug Administration‒approved nicotine replacement therapy sales data and consumer preferences for nicotine replacement therapy attributes (e.g., flavor). Examination of consumer preferences may inform both public health smoking cessation programs as well as subsequent research on consumer preferences for potentially reduced-risk tobacco products U.S. Food and Drug Administration may authorize.


      NielsenIQ Retail Measurement Service data were used to examine national trends in over-the-counter nicotine replacement therapy dollar sales from 2017 to 2020 and dollar sales by retail channel and product attributes for the most recent year available at the time of analysis (2020).


      Over-the-counter nicotine replacement therapy sales totaled about $1 billion annually between 2017 and 2020. Across the 4-year period, sales of gum and patches decreased, whereas lozenge sales increased (p<0.05 for all). In 2020, gum accounted for 52.7% ($511 million), lozenges accounted for 33.3% ($322 million), and patches accounted for 14.1% ($137 million) of over-the-counter nicotine replacement therapy sales. Drug stores were the retail channel accounting for the largest percentage of total over-the-counter nicotine replacement therapy sales (42.9%). Three leading brands―private label or store brands (62.8%), Nicorette (30.7%,), and NicoDerm CQ (5.7%)―accounted for 99.2% of the total over-the-counter nicotine replacement therapy market. Mint was the most common flavor, representing 41.2% of total gum and 73.6% of total lozenge sales.


      This analysis of over-the-counter nicotine replacement therapy sales sheds light on consumer preferences for attributes that can inform efforts to facilitate smoking cessation and research on preferences related to potentially reduced-risk tobacco products.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wang TW
        • Asman K
        • Gentzke AS
        • et al.
        Tobacco product use among adults – United States, 2017.
        MMWR Morb Mortal Wkly Rep. 2018; 67: 1225-1232
        • HHS
        The health consequences of smoking—50 years of progress: a report of the Surgeon General.
        HHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA2014 (PublishedAccessed May 20, 2020)
        • HHS
        Smoking cessation: a report of the Surgeon General.
        HHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA2020 (PublishedAccessed May 20, 2020)
      1. Treating tobacco use and dependence: 2008 update.
        Agency for Healthcare Research and Quality, 2020 (Updated FebruaryAccessed May 20, 2020)
        • He J
        • Wang X
        • Vandenbosch MB
        • Nault BR.
        Revealed preference in online reviews: purchase verification in the tablet market.
        Decis Support Syst. 2020; 132113281
        • Leguizamon SJ
        • Ross JM.
        Revealed preference for relative status: evidence from the housing market.
        J Hous Econ. 2012; 21: 55-65
        • Arnot C
        • Boxall PC
        • Cash SB.
        Do ethical consumers care about price? A revealed preference analysis of fair trade coffee purchases.
        Canadian J Agric Econ. 2006; 54: 555-565
        • Earnhart D.
        Combining revealed and stated data to examine housing decisions using discrete choice analysis.
        J Urban Econ. 2002; 51: 143-169
        • Babb S
        • Malarcher A
        • Schauer G
        • Asman K
        • Jamal A.
        Quitting smoking among adults – United States, 2000–2015.
        MMWR Morb Mortal Wkly Rep. 2017; 65: 1457-1464
        • Babb S
        • Malarcher A
        • Asman K
        • et al.
        Disparities in cessation behaviors between Hispanic and non-Hispanic white adult cigarette smokers in the United States, 2000–2015.
        Prev Chronic Dis. 2020; 17: E10
        • Zhang L
        • Babb S
        • Schauer G
        • Asman K
        • Xu X
        • Malarcher A.
        Cessation behaviors and treatment use among U.S. smokers by insurance status, 2000–2015.
        Am J Prev Med. 2019; 57: 478-486
        • Sedjo RL
        • Li Y
        • Levinson AH.
        Smoking-cessation treatment: use trends among non-Hispanic white and English-speaking Hispanic/Latino smokers, Colorado 2001–2012.
        Am J Prev Med. 2016; 51: 232-239
        • Kasza KA
        • Cummings KM
        • Carpenter MJ
        • Cornelius ME
        • Hyland AJ
        • Fong GT.
        Use of stop-smoking medications in the United States before and after the introduction of varenicline.
        Addiction. 2015; 110: 346-355
        • Jarlenski M
        • Hyon Baik S
        • Zhang Y
        Trends in use of medications for smoking cessation in Medicare, 2007–2012.
        Am J Prev Med. 2016; 51: 301-308
        • Kahende J
        • Malarcher A
        • England L
        • et al.
        Utilization of smoking cessation medication benefits among Medicaid fee-for-service enrollees 1999–2008.
        PLoS One. 2017; 12e0170381
        • Yue X
        • Guo JJ
        • Wigle PR.
        Trends in utilization, spending, and prices of smoking-cessation medications in Medicaid programs: 25 years empirical data analysis, 1991–2015.
        Am Health Drug Benefits. 2018; 11 (Accessed January 19, 2023): 275-285
        • Tibuakuu M
        • Okunrintemi V
        • Jirru E
        • et al.
        National trends in cessation counseling, prescription medication use, and associated costs among U.S. adult cigarette smokers.
        JAMA Netw Open. 2019; 2e194585
        • Ku L
        • Bruen BK
        • Steinmetz E
        • Bysshe T.
        Medicaid tobacco cessation: big gaps remain in efforts to get smokers to quit.
        Health Aff (Millwood). 2016; 35: 62-70
        • Desai RJ
        • Good MM
        • San-Juan-Rodriguez A
        • et al.
        Varenicline and nicotine replacement use associated with U.S. Food and Drug Administration safety communications.
        JAMA Netw Open. 2019; 2e1910626
        • Scharf D
        • Fabian T
        • Fichter-DeSando C
        • Douaihy A.
        Nicotine replacement prescribing trends in a large psychiatric hospital, before and after implementation of a hospital-wide smoking ban.
        Nicotine Tob Res. 2011; 13: 466-473
        • Burton SL
        • Gitchell JG
        • Shiffman S
        • Centers for Disease Control and Prevention (CDC)
        Use of FDA-approved pharmacologic treatments for tobacco dependence–United States, 1984–1998.
        MMWR Morb Mortal Wkly Rep. 2000; 49: 665-668
        • Shiffman S
        • Hughes JR
        • Pillitteri JL
        • Burton SL.
        Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample.
        Tob Control. 2003; 12: 310-316
        • Hu T
        • Sung HY
        • Keeler TE
        • Marciniak M.
        Cigarette consumption and sales of nicotine replacement products.
        Tob Control. 2000; 9: II60-II63
        • Metzger KB
        • Mostashari F
        • Kerker BD.
        Use of pharmacy data to evaluate smoking regulations’ impact on sales of nicotine replacement therapies in New York City.
        Am J Public Health. 2005; 95: 1050-1055
        • Huang J
        • Wang Y
        • Duan Z
        • Kim Y
        • Emery SL
        • Chaloupka FJ.
        Do e-cigarette sales reduce the demand for nicotine replacement therapy (NRT) products in the U.S.? Evidence from the retail sales data.
        Prev Med. 2021; 145106376
        • Huang J
        • Gwarnicki C
        • Xu X
        • Caraballo RS
        • Wada R
        • Chaloupka FJ.
        A comprehensive examination of own- and cross-price elasticities of tobacco and nicotine replacement products in the U.S.
        Prev Med. 2018; 117: 107-114
        • Tauras JA
        • Chaloupka FJ
        • Emery S.
        The impact of advertising on nicotine replacement therapy demand.
        Soc Sci Med. 2005; 60: 2351-2358
        • Tauras JA
        • Chaloupka FJ.
        The demand for nicotine replacement therapies.
        Nicotine Tob Res. 2003; 5: 237-243
        • Bandi P
        • Asare S
        • Majmundar A
        • et al.
        Changes in smoking cessation-related behaviors among U.S. adults during the COVID-19 pandemic.
        JAMA Netw Open. 2022; 5e2225149
      2. Consumer price index. U.S. Bureau of Labor Statistics. Updated May 26, 2021. Accessed May 26, 2021.

        • Davey AM
        • Flores BE.
        Identification of seasonality in time series: a note.
        Math Comput Modell. 1993; 18: 73-81
        • Hirsch RM
        • Slack JR.
        A nonparametric trend test for seasonal data with serial dependence.
        Water Resour Res. 1984; 20: 727-732
        • Hipel KW
        • McLeod AI.
        Time Series Modelling of Water Resources and Environmental Systems. Elsevier Science, New York, NY1994 (Accessed January 19, 2023)
        • Libiseller C
        • Grimvall A.
        Performance of partial Mann-Kendall tests for trend detection in the presence of covariates.
        Environmetrics. 2002; 13: 71-84
        • Kim HJ
        • Fay MP
        • Feuer EJ
        • Midthune DN.
        Permutation tests for joinpoint regression with applications to cancer rates [published correction appears in Stat Med. 200128;20(4):655].
        Stat Med. 2000; 19: 335-351;2-Z
        • Wadgave U
        • Nagesh L.
        Nicotine replacement therapy: an overview.
        Int J Health Sci (Qassim). 2016; 10: 425-435
        • Federal Trade Commission
        Cigarette report for 2020.
        Federal Trade Commission, Washington, DC2021 (Accessed April 18, 2021)
        • Cornelius ME
        • Loretan CG
        • Wang TW
        • Jamal A
        • Homa DM.
        Tobacco product use among adults – United States, 2020.
        MMWR Morb Mortal Wkly Rep. 2022; 71: 397-405
        • Centers for Disease Control and Prevention
        Identifying and treating patients who use tobacco: action steps for clinicians.
        Centers for Disease Control and Prevention, US Dept of Health and Human Services, Atlanta, GA2016 (Accessed January 19, 2023)
        • Hammond D
        • Reid JL
        • Driezen P
        • et al.
        Smokers’ use of nicotine replacement therapy for reasons other than stopping smoking: findings from the ITC four country survey [published correction appears in Addiction. 2008;103(12):2075].
        Addiction. 2008; 103: 1696-1703
        • Centers for Medicare and Medicaid Services
        FAQs about Affordable Care Act implementation (part XIX).
        Centers for Medicare and Medicaid Services, Baltimore, MD2014 (Published May 2Accessed May 20, 2020)